Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.
The SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on 01/31/2006.
![]() XBI 2 months ago | Other | MX$0.11 Per Share |
![]() XBI 5 months ago | Other | MX$0.05 Per Share |
![]() XBI 8 months ago | Other | MX$0.29 Per Share |
![]() XBI 11 months ago | Other | MX$2.07 Per Share |
![]() XBI 18 Dec 2023 | Other | MX$0.24 Per Share |
![]() XBI 2 months ago | Other | MX$0.11 Per Share |
![]() XBI 5 months ago | Other | MX$0.05 Per Share |
![]() XBI 8 months ago | Other | MX$0.29 Per Share |
![]() XBI 11 months ago | Other | MX$2.07 Per Share |
![]() XBI 18 Dec 2023 | Other | MX$0.24 Per Share |
XMEX Exchange | US Country |
The provided company is a financial entity that focuses on mirroring the performance of the S&P Biotechnology Select Industry Index. By employing a sampling strategy, the fund aims to invest predominantly, if not entirely, in the components that make up the index. This index is a representation of the biotechnology segment of the S&P Total Market Index (S&P TMI), encompassing companies within the biotechnology industry. The strategy includes investing at least 80% of its total assets in the securities that form part of the index, ensuring a strong alignment with the biotechnology sector's market movements.
This product is designed for investors seeking exposure to the biotechnology sector. The fund tracks the S&P Biotechnology Select Industry Index, which is a subset of the larger S&P Total Market Index (S&P TMI) focused specifically on the biotechnology industry. By putting a significant portion of its assets—substantially all, but at a minimum, 80%—into the securities that compose the index, the fund offers a direct pathway for investment in a diversified portfolio of biotechnology companies. The sampling strategy employed aims to replicate the index's performance, making it an attractive option for those looking to invest in the biotechnology industry through a mechanism that mirrors its market dynamics closely.